Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;24(6):689-698.
doi: 10.1007/s11886-022-01694-5. Epub 2022 Mar 29.

A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?

Neil S Maitra  1 , Dhruv Mahtta  2   3 , Sankar Navaneethan  4   5 , Elizabeth M Vaughan  1   6 , Ajar Kochar  7 , Martha Gulati  8 , Glenn N Levine  2   9 , Laura A Petersen  3   10 , Salim S Virani  11   12   13   14   15
Affiliations
Review

A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?

Neil S Maitra et al. Curr Cardiol Rep. 2022 Jun.

Abstract

Purpose of review: To review the factors contributing to underutilization of guideline-directed therapies, identify strategies to alleviate these factors, and apply these strategies for effective and timely dissemination of novel cardioprotective glucose-lowering agents.

Recent findings: Recent analyses demonstrate underutilization of cardioprotective glucose lowering agents despite guideline recommendations for their use. Major contributors to underutilization of guideline-directed therapies include therapeutic inertia, perceptions about side effects, and factors found at the level of the clinicians, patients, and the healthcare system. The recent emergence of several novel therapies, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, for use in cardiovascular disease provides a unique avenue to improve patient outcomes. To effectively utilize novel cardioprotective glucose lowering agents to improve cardiovascular outcomes, clinicians must recognize and learn from prior barriers to application of guideline-directed therapies. Further endeavors are prudent to ensure uptake of novel agents.

Keywords: Glucose-lowering agents; Statins; Therapeutic inertia; Utilization.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262–76. https://doi.org/10.1016/S0140-6736(21)00536-5 . - DOI
    1. Maddox TM, Januzzi JL, Allen LA, Breathett K, Butler J, Davis LL, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022 . - DOI - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. https://doi.org/10.1161/CIR.0000000000000625 . - DOI - PubMed
    1. Kohn LT, Corrigan JM, Donaldson MS. Institute of Medicine (US) Committee on Quality of Health Care in America. To err is human: building a safer health system. Washington, DC: National Academies. 2000.
    1. Scandinavian Simvastatin Survival Study G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet (British edition). 1994;344(8934):1383–9. https://doi.org/10.1016/S0140-6736(94)90566-5 .

Publication types

MeSH terms

Substances

LinkOut - more resources